Literature DB >> 8985348

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival.

A Watson1, J Ranchalis, B Travis, J McClure, W Sutton, P R Johnson, S L Hu, N L Haigwood.   

Abstract

A reliable method for the quantitation of plasma viremia in nonhuman primates infected with simian immunodeficiency virus (SIV) and related viruses is described. This method is based on an established quantitative-competitive PCR format and includes a truncated control for internal assay calibration. Optimization of assay conditions has significantly improved amplification specificity, and interassay variability is comparable to that of commercially available assays for human immunodeficiency virus (HIV) quantitation. This procedure was used to monitor viral loads in a group of Macaca mulatta animals that were infected with SIVsmE660 for over 2 years. Highly diverse profiles of plasma viremia were observed among animals, and high viral loads were associated with more rapid disease progression. Spearman rank correlation analyses were done for survival versus three parameters of viral load: plasma viremia, p27 core antigen, and frequency of infected peripheral blood mononuclear cells. Plasma viremia had the strongest overall correlation and was significantly (P < 0.05 to P < 0.01) associated with survival at 10 of the 13 time points examined. Plasma viremia did not correlate with survival during the primary viremia phase; however, the strength of this correlation increased with time postinfection and, remarkably, viremia levels as early as week 6 postinfection were highly predictive (P < 0.01) of relative survival. These findings are consistent with the available clinical data concerning viral load correlates early in HIV infection, and they provide further support for the view that disease outcome in lentiviral infection may be largely determined by events that occur shortly after infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985348      PMCID: PMC191049     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

2.  Long-term survivors with continuously high levels of HIV type 1.

Authors:  J A Rump; H H Peter; J Schneider; O Haller; A Meyerhans
Journal:  AIDS Res Hum Retroviruses       Date:  1996-06-10       Impact factor: 2.205

3.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

4.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Authors:  V M Hirsch; T R Fuerst; G Sutter; M W Carroll; L C Yang; S Goldstein; M Piatak; W R Elkins; W G Alvord; D C Montefiori; B Moss; J D Lifson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology.

Authors:  J Todd; C Pachl; R White; T Yeghiazarian; P Johnson; B Taylor; M Holodniy; D Kern; S Hamren; D Chernoff
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995

6.  HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS.

Authors:  K Saksela; C E Stevens; P Rubinstein; P E Taylor; D Baltimore
Journal:  Ann Intern Med       Date:  1995-11-01       Impact factor: 25.391

7.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

8.  High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.

Authors:  C Rinaldo; X L Huang; Z F Fan; M Ding; L Beltz; A Logar; D Panicali; G Mazzara; J Liebmann; M Cottrill
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.

Authors:  Y Cao; D D Ho; J Todd; R Kokka; M Urdea; J D Lifson; M Piatak; S Chen; B H Hahn; M S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

10.  Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.

Authors:  D R Henrard; E Daar; H Farzadegan; S J Clark; J Phillips; G M Shaw; M P Busch
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-07-01
View more
  94 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus.

Authors:  S Goldstein; I Ourmanov; C R Brown; B E Beer; W R Elkins; R Plishka; A Buckler-White; V M Hirsch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.

Authors:  Claire Ham; Priya Srinivasan; Rigmor Thorstensson; Ernst Verschoor; Zahra Fagrouche; Leonardo Sernicola; Artur Ramos; Fausto Titti; Neil Almond; Neil Berry
Journal:  J Clin Microbiol       Date:  2010-04-28       Impact factor: 5.948

6.  Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.

Authors:  Christopher W Peterson; Patrick Younan; Patricia S Polacino; Nicholas J Maurice; Hannah W Miller; Martin Prlic; Keith R Jerome; Ann E Woolfrey; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  J Med Primatol       Date:  2013-10       Impact factor: 0.667

7.  High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx.

Authors:  Richard Onanga; Christopher Kornfeld; Ivona Pandrea; Jerome Estaquier; Sandrine Souquière; Pierre Rouquet; Virginie Poaty Mavoungou; Olivier Bourry; Souleymane M'Boup; Françoise Barré-Sinoussi; François Simon; Cristian Apetrei; Pierre Roques; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease.

Authors:  John P Capitanio; Kristina Abel; Sally P Mendoza; Shelley A Blozis; Michael B McChesney; Steve W Cole; William A Mason
Journal:  Brain Behav Immun       Date:  2007-08-23       Impact factor: 7.217

9.  The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques.

Authors:  Mireille Laforge; Ricardo Silvestre; Vasco Rodrigues; Julie Garibal; Laure Campillo-Gimenez; Shahul Mouhamad; Valérie Monceaux; Marie-Christine Cumont; Henintsoa Rabezanahary; Alain Pruvost; Anabela Cordeiro-da-Silva; Bruno Hurtrel; Guido Silvestri; Anna Senik; Jérôme Estaquier
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

10.  Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics.

Authors:  R A Parker; M M Regan; K A Reimann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.